The New York Times article/opinion piece cheynew posted a short time ago provides a response that is more eloquent than I could provide, Vin. I have no doubt that BMY continues now to look for combination therapy molecules to combine with Opdivo, just as AZN/PPHM are doing for Durvalumumab. The reason is expressed here, in case you missed it:
Market Data 
Markets 
AI
